Isatuximab is used in combination with pomalidomide and dexamethasone (pom-dex) for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor; it is also used in combination with carfilzomib and dexamethasone (Kd) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1–3 prior lines of therapy.